Crinetics Pharmaceuticals
Stage
Spinoff / SpinoutTotal Raised
$103.5MInvestors Count
7Deal Terms
3Portfolio Exits
1Funding, Valuation & Revenue
4 Fundings
Crinetics Pharmaceuticals has raised $103.5M over 4 rounds.
Crinetics Pharmaceuticals's latest funding round was a IPO for $102M on July 18, 2018.
Crinetics Pharmaceuticals's latest post-money valuation is from July 2018.
Sign up for a free demo to see Crinetics Pharmaceuticals's valuations in July 2018 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
7/18/2018 | IPO | $102M | 1 | |||
7/1/2018 | Unattributed VC | |||||
2/23/2018 | Series B | |||||
11/2/2015 | Series A |
Date | 7/18/2018 | 7/1/2018 | 2/23/2018 | 11/2/2015 |
|---|---|---|---|---|
Round | IPO | Unattributed VC | Series B | Series A |
Amount | $102M | |||
Investors | ||||
Valuation | ||||
Revenue | ||||
Sources | 1 |
Crinetics Pharmaceuticals Deal Terms
3 Deal Terms
Crinetics Pharmaceuticals's deal structure is available for 3 funding rounds, including their IPO from July 18, 2018.
Round | IPO | Series B | Series A |
|---|---|---|---|
Funding Date | |||
Pre-Money Valuation | |||
Post-Money Valuation | |||
Amount Raised | |||
Shares Authorized | |||
Issuance Price | |||
Dividend Rate | |||
Liquidation Preferences | |||
Liquidation Price | |||
Participation | |||
Conversion Price | |||
Anti Dilution | |||
General Voting | |||
Board Voting | |||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IPO | |||||||||||||||
Series B | |||||||||||||||
Series A |
Crinetics Pharmaceuticals Investors
7 Investors
Crinetics Pharmaceuticals has 7 investors. Novo Ventures invested in Crinetics Pharmaceuticals's Unattributed VC funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
7/1/2018 | 7/1/2018 | 1 Unattributed VC | Corporate Venture | California | ||
Venture Capital | California | |||||
Venture Capital | California | |||||
Venture Capital | California | |||||
Asset/Investment Management | Massachusetts |
First funding | 7/1/2018 | ||||
|---|---|---|---|---|---|
Last Funding | 7/1/2018 | ||||
Investor | |||||
Rounds | 1 Unattributed VC | ||||
Board Seats | |||||
Type | Corporate Venture | Venture Capital | Venture Capital | Venture Capital | Asset/Investment Management |
Location | California | California | California | California | Massachusetts |
Crinetics Pharmaceuticals Portfolio Exits
1 Portfolio Exit
Crinetics Pharmaceuticals has 1 portfolio exit. Their latest portfolio exit was Radionetics Oncology on October 18, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
10/18/2021 | Spinoff / Spinout | Radionetics Oncology | 1 |
Date | 10/18/2021 |
|---|---|
Exit | Spinoff / Spinout |
Companies | Radionetics Oncology |
Valuation | |
Acquirer | |
Sources | 1 |
Loading...